At the María Curie provincial cancer hospital, national clinical trials with therapeutic vaccines are being carried out, linked to the Molecular Immunology (CIM) and Genetic Engineering and Biotechnology (CIGB) centers.

The recombinant anti-tick vaccine Gavac®, produced since 1996 in the Center of Genetic Engineering and Biotechnology (CIGB, Spanish acronym) in Camagüey, has experienced over the last three years a steady increase in its demand in Cuba.

The recombinant vaccine against ticks Gavac, produced in the Center of Genetic Engineering and Biotechnology (CIGB), of this city, continues its application in the Cuban cattle mass, in the determination to resist the harmful effects that this arachnid causes.